JOGO Health develops a wearable device and companion app that leverage the brain's neuroplasticity to deliver non-invasive, drug-free relief for conditions including chronic lower back pain, stroke recovery, migraines, and incontinence. Its solution is FDA-cleared and reimbursed by Medicare and commercial insurance. The company holds 18 patent claims across neuromuscular conditions and is targeting a $380B market without drugs or surgery. JOGO has treated more than 25,000 patients and completed over 100,000 sessions through 50+ hospital channel partners, including Mayo Clinic, Mount Sinai Hospital, and Brigham and Women's Hospital. The founding team includes experienced healthcare entrepreneurs with backgrounds at Columbia, Harvard, Yale, AT&T, Johnson & Johnson, and AstraZeneca; CEO Sanjai Murali led the company to FDA market authorization. The company plans to use new capital to support its commercial launch and scale to meet growing demand, positioning its technology as a first-line treatment for chronic pain and neuromuscular disorders.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024